


Accepted Manuscript

Income is an independent risk factor for worse asthma outcomes

Juan Carlos Cardet, MD, Margee Louisias, MD, MPH, Tonya S. King, PhD, Mario Castro, MD, MPH, Christopher D. Codispoti, MD, PhD, Ryan Dunn, MD, Linda Engle, BS, B. Louise Giles, MD, Fernando Holguin, MD, MPH, John J. Lima, PharmD, Dayna Long, MD, Njira Lugogo, MD, Sharmilee Nyenhuis, MD, Victor E. Ortega, MD, PhD, Sima Ramratnam, MD, MPH, Michael E. Wechsler, MD, MMSc, Elliot Israel, MD, Wanda Phipatanakul, MD, MS



PII: S0091-6749(17)30792-3

DOI: [10.1016/j.jaci.2017.04.036](https://doi.org/10.1016/j.jaci.2017.04.036)

Reference: YMAI 12815

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 20 October 2016

Revised Date: 17 February 2017

Accepted Date: 4 April 2017

Please cite this article as: Cardet JC, Louisias M, King TS, Castro M, Codispoti CD, Dunn R, Engle L, Giles BL, Holguin F, Lima JJ, Long D, Lugogo N, Nyenhuis S, Ortega VE, Ramratnam S, Wechsler ME, Israel E, Phipatanakul W, the 'VIDA Disparities' Working Group members, on behalf of the AsthmaNet investigators, Income is an independent risk factor for worse asthma outcomes, *Journal of Allergy and Clinical Immunology* (2017), doi: 10.1016/j.jaci.2017.04.036.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Word count** (body): 2511 (initial), 3031 (as of 4/21/17) (max 3500)

2 **Word count** (abstract): 226 (max 250)

3

4 **Title:** Income is an independent risk factor for worse asthma outcomes

5

6 **Authors:** Juan Carlos Cardet MD^{1*}; Margee Louisias MD, MPH^{1,2*}; Tonya S. King PhD³; Mario Castro
7 MD, MPH⁴; Christopher D. Codispoti MD, PhD⁵; Ryan Dunn MD⁶; Linda Engle BS³; B. Louise Giles
8 MD⁷; Fernando Holguin MD, MPH⁸; John J. Lima PharmD⁹; Dayna Long MD¹⁰; Njira Lugogo MD¹¹,
9 Sharmilee Nyenhuis MD^{12,13}; Victor E. Ortega, MD, PhD¹⁴; Sima Ramratnam, MD, MPH¹⁵; Michael E.
10 Wechsler, MD, MMSc³; Elliot Israel MD^{1#}; and Wanda Phipatanakul, MD, MS^{1,2#}, the 'VIDA Disparities'
11 Working Group members, on behalf of the AsthmaNet investigators.

12 *Contributed equally as first authors

13 #Contributed equally as senior authors

14

15 **Author affiliations:** 1: Department of Medicine, Brigham and Women's Hospital, Boston, MA. 2:
16 Boston Children's Hospital, Boston, MA. 3: Department of Public Health Sciences, Penn State College
17 of Medicine, Hershey, PA. 4: Washington University School of Medicine, St Louis, MO. 5: Rush
18 University, Chicago, IL. 6: National Jewish Health, Denver, CO. 7: University of Chicago, Chicago, IL. 8:
19 University of Pittsburgh School of Medicine, Pittsburgh, PA. 9: Nemours Children's Health System,
20 Jacksonville, FL. 10: Department of Pediatrics, University of California at San Francisco's Benioff
21 Children's Hospital at Oakland, Oakland, CA. 11: Duke University, Durham, NC. 12: University of Illinois
22 at Chicago, IL. 13: University of Illinois Hospital & Health Sciences System, Chicago, IL. 14: Center for
23 Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem,
24 NC. 15: University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

25 **Corresponding author:** Wanda Phipatanakul, MD, MS, Boston Children's Hospital, 300 Longwood
26 Avenue, Fegan Building 7th floor, Boston, MA 02115, wanda.phipatanakul@childrens.harvard.edu
27 (617) 355-6117

28 **Summary conflict of interest statements** for each author (or a statement indicating no conflicts exist
29 for the specified author[s]): MEW has received honoraria from Boston Scientific, Teva, Novartis,
30 Boehringer Ingelheim, Sanofi, Regeneron Vectura, Sunovion, Ambit Bioscience, Meda, Mylan, Tunitas,
31 Genentech, Theravance, and AstraZeneca. Other authors have no conflicts of interest.

32 **Funding information:** this study was conducted with the support of grants HL098102, U10HL098096,
33 UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177,
34 UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and
35 HL098115 that were awarded by the National Heart, Lung, and Blood Institute. In addition, Dr. Cardet
36 received funds from a NIAID diversity supplement 3U19AI095219-04S1. Dr. Louisias was supported by
37 NIH grant K12HS022986 and 5T32 HS00063-21. Dr. Phipatanakul received funds from NIAID K24AI
38 106822.

39

Download English Version:

<https://daneshyari.com/en/article/8713515>

Download Persian Version:

<https://daneshyari.com/article/8713515>

[Daneshyari.com](https://daneshyari.com)